Inspire Pharmaceuticals announced that it shuttered a mid-stage drug trial on the recommendation of its data monitoring committee after seeing data on a "range of bleeding complications among volunteers. There were no deaths reported among the 160 participants in the trial, who were taking the experimental INS50589 Antiplatelet after undergoing coronary artery bypass graft surgery utilizing a cardiopulmonary bypass pump. The company said it would undertake a thorough review of what happened in the trial, but added it was likely that Inspire would reallocate its resources to its other drug candidates.
- here's the AP report on Inspire's trial